Scholarlink

<p>Langerhans cell sarcoma (LCS) is an aggressive malignant neoplasm with a Langerhans cell immunophenotype and high-grade cytological features. Occasionally, it can coexist with other hematopoietic neoplasms with proven clonal relationship. Most of these neoplasms were found to be of lymphoid origin. This phenomenon is usually explained as lineage plasticity. Although, to the best of our knowledge, the coexistence of LCS and myeloproliferative neoplasm (MPN) with proven clonal relationship has never been reported. Herein, we describe a case of a 79-year-old man with MPN, who developed LCS 2 years after original diagnosis. Biopsy and pathological evaluation revealed a high-grade malignant neoplasm, identified as LCS with expressing CD1a, langerin, and S100. The next-generation sequencing performed on skin and bone marrow biopsies showed identical mutations in <i>ASXL1</i>,<i> CALR</i>, and <i>TET2</i> genes, while the LCS tumor showed an additional <i>BRAF</i> mutation. This case presents the case of progression of MPN to LCS supported by molecular evidence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

BRAF positive Langerhans cell sarcoma arising from CALR positive myeloproliferative neoplasm: evidence of a clonal progenitor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月8日

查看全文
  • Zohre Sadeghian,
  • Kirill A. Lyapichev,
  • Chieh Lin Fu,
  • Gulrukh Botiralieva,
  • Maria Julia Diacovo,
  • Amir Behdad

摘要

Langerhans cell sarcoma (LCS) is an aggressive malignant neoplasm with a Langerhans cell immunophenotype and high-grade cytological features. Occasionally, it can coexist with other hematopoietic neoplasms with proven clonal relationship. Most of these neoplasms were found to be of lymphoid origin. This phenomenon is usually explained as lineage plasticity. Although, to the best of our knowledge, the coexistence of LCS and myeloproliferative neoplasm (MPN) with proven clonal relationship has never been reported. Herein, we describe a case of a 79-year-old man with MPN, who developed LCS 2 years after original diagnosis. Biopsy and pathological evaluation revealed a high-grade malignant neoplasm, identified as LCS with expressing CD1a, langerin, and S100. The next-generation sequencing performed on skin and bone marrow biopsies showed identical mutations in ASXL1, CALR, and TET2 genes, while the LCS tumor showed an additional BRAF mutation. This case presents the case of progression of MPN to LCS supported by molecular evidence.